Image_7_Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.tif
Systematic assessment of PD-1/PD-L1 inhibitor-related neurological toxicities is important for guiding anti-PD-1 and anti-PD-L1 immunotherapy. Therefore, we conducted this meta-analysis to reveal the relationship between PD-1/PD-L1 inhibitors and neurological toxicities among cancer patients.
MethodsClinical trials investigating PD-1/PD-L1 inhibitors in cancer patients were identified by a systematic search of PubMed. The random-effect model was used to synthesize individual studies. Neurological toxicities, including all-grades and grades 3–5, were taken into account for the final comprehensive meta-analysis. The Newcastle Ottawa Scale (NOS) was used to assess the quality of included trials.
ResultsThirty-one clinical trials containing data of neurological toxicities were included. Compared with chemotherapy, the risk of all-grade neurological toxicities caused by PD-1/PD-L1 inhibitors was much lower in terms of peripheral neuropathy [OR = 0.07, 95%CI:(0.04, 0.13)], peripheral sensory neuropathy [OR = 0.07, 95%CI(0.04, 0.12)], dysgeusia [OR = 0.26, 95%CI:(0.19, 0.35)], paraesthesia [OR = 0.23, 95%CI:(0.14, 0.36)], and polyneuropathy [OR = 0.12, 95%CI:(0.01, 0.94)]. However, for grades 3–5, the statistically significant results were only seen in peripheral neuropathy [OR = 0.15, 95%CI:(0.07, 0.34)] and peripheral sensory neuropathy [OR = 0.13, 95%CI:(0.04, 0.40)]. No statistically significant difference regarding the risk of headache, dizziness, and Guillain–Barré syndrome was found between PD-1/PD-L1 inhibitors and chemotherapy. For PD-1/PD-L1 inhibitors plus chemotherapy, the risk trends of the above-mentioned neurological toxicities, especially grades 3–5 peripheral neuropathy [OR = 1.76, 95%CI:(1.10, 2.82)] was increased compared to chemotherapy alone.
ConclusionOur comprehensive analysis showed that PD-1/PD-L1 inhibitors alone exhibited lower neurological toxicities than chemotherapy. However, the risk of headache, dizziness, and Guillain–Barré syndrome was similar between PD-1/PD-L1 and chemotherapy. For PD-1/PD-L1 inhibitors plus chemotherapy, the incidence trend of neurological toxicities would be increased, especially for peripheral neuropathy of grades 3–5.
History
References
- https://doi.org//10.3322/caac.21596
- https://doi.org//10.6004/jnccn.2018.0047
- https://doi.org//10.1056/NEJMra1703481
- https://doi.org//10.1200/JCO.2017.77.6385
- https://doi.org//10.1634/theoncologist.2016-0487
- https://doi.org//10.1186/s40425-019-0617-x
- https://doi.org//10.1016/j.ejca.2016.12.001
- https://doi.org//10.1097/WCO.0000000000000503
- https://doi.org//10.1093/neuonc/nou001
- https://doi.org//10.1093/annonc/mdw126
- https://doi.org//10.3988/jcn.2019.15.2.259
- https://doi.org//10.1212/NXI.0000000000000439
- https://doi.org//10.1186/s40425-017-0300-z
- https://doi.org//10.3390/cancers11030296
- https://doi.org//10.7326/0003-4819-151-4-200908180-00135
- https://doi.org//10.3389/fonc.2019.00866
- https://doi.org//10.1136/bmj.d5928
- https://doi.org//10.2307/2533446
- https://doi.org//10.1136/bmj.315.7109.629
- https://doi.org//10.1136/bmj.327.7414.557
- https://doi.org//10.1056/NEJMoa1816047
- https://doi.org//10.1016/S0140-6736(19)30723-8
- https://doi.org//10.1016/S0140-6736(18)32409-7
- https://doi.org//10.1016/S0140-6736(18)31999-8
- https://doi.org//10.1056/NEJMoa1809615
- https://doi.org//10.1056/NEJMoa1809064
- https://doi.org//10.1056/NEJMoa1716948
- https://doi.org//10.1056/NEJMoa1810865
- https://doi.org//10.1016/S1470-2045(18)30673-9
- https://doi.org//10.1016/S0140-6736(18)31257-1
- https://doi.org//10.1016/S0140-6736(17)33297-X
- https://doi.org//10.1016/j.cllc.2018.01.004
- https://doi.org//10.1056/NEJMoa1613683
- https://doi.org//10.1016/S0140-6736(16)32517-X
- https://doi.org//10.1016/S1470-2045(16)30498-3
- https://doi.org//10.1056/NEJMoa1606774
- https://doi.org//10.1056/NEJMoa1602252
- https://doi.org//10.1016/S1470-2045(19)30018-X
- https://doi.org//10.1016/S0140-6736(16)00587-0
- https://doi.org//10.1016/S0140-6736(15)01281-7
- https://doi.org//10.1016/S1470-2045(16)30366-7
- https://doi.org//10.1056/NEJMoa1507643
- https://doi.org//10.1056/NEJMoa1504627
- https://doi.org//10.1056/NEJMoa1510665
- https://doi.org//10.1016/S1470-2045(19)30626-6
- https://doi.org//10.1056/NEJMoa1801005
- https://doi.org//10.1038/s41591-019-0448-9
- https://doi.org//10.1016/S0140-6736(19)32222-6
- https://doi.org//10.1056/NEJMoa1910549
- https://doi.org//10.1016/S1470-2045(18)30700-9
- https://doi.org//10.1056/NEJMoa1709684
- https://doi.org//10.1056/NEJMoa1504030
- https://doi.org//10.1056/NEJMoa1910836
- https://doi.org//10.1056/NEJMoa1709937
- https://doi.org//10.1056/NEJMoa1809697
- https://doi.org//10.1016/S1470-2045(19)30519-4
- https://doi.org//10.1016/0197-2456(86)90046-2
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity